ReviewBest practice & research. Clinical rheumatology2021
COVID-19 pandemic management and the rheumatology patient.
Review in Best practice & research. Clinical rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
- Long-Term Safety of Rituximab (Risks of Viral and Opportunistic Infections).Current rheumatology reports · 2021Review
- Changes in Eating Habits and Sedentary Behavior During the COVID-19 Pandemic in Adolescents With Chronic Conditions.Frontiers in pediatrics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We discuss the evidence behind mask use, including evidence for homemade masks, social distancing, and the local coronavirus disease-2019 (COVID-19) epidemics in countries that initially employed more limited public health interventions. Given the absence of data for specific interventions in the rheumatic disease population, we reviewed the evidence available for the general population. The risk of poor outcomes with COVID-19 in patients with rheumatic diseases is a potential concern given the immunosuppression associated with these conditions and disease-modifying anti-rheumatic drug therapy, as well as advancing age and many of the comorbidities present in such patients. Infection prevention is key, for both individual patients and their community. Given the data collected from the general population, we recommend ongoing proper mask use, social distancing, and hand hygiene for patients with rheumatic diseases and encourage providers to counsel these patients in prevention strategies and attempt to dispel abundant misinformation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.